Lysoclear, Inc. is a pre-clinical Ichor Therapeutics portfolio company that develops enzyme therapies for eye disease. The company is currently developing leads to treat atrophic “dry” age-related macular degeneration and Stargardt’s macular degeneration.
Age-related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD) are thought to arise from the gradual loss of retinal pigmented epithelial (RPE) cells of the macula, the area of the eye responsible for central vision. The accumulation of toxic vitamin A aggregates, including the bis-retinoid A2E, have been implicated in these diseases.
Recent research suggests that A2E is capable of binding native lysosomal enzymes, inhibiting their function. As A2E accumulation reaches a critical threshold, lysosomal impairment leads to the accumulation of intracellular lipofuscin, extracellular drusen deposition, and eventually RPE cell death.
Lysoclear is a recombinant enzyme product under development by Ichor Therapeutics that is able to selectively localize to the lysosomes of RPE cells where A2E accumulates, and destroy it.